Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer.
from Top Health News -- ScienceDaily https://ift.tt/6xt9QEw
No comments:
Post a Comment